


**Med, Volume 2**

## **Supplemental information**


### **Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes**

**Edwards Pradenas, Benjamin Trinité, Víctor Urrea, Silvia Marfil, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Ferran Tarrés-Freixas, Silvia Pérez-Yanes, Carla Rovirosa, Erola Ainsua-Enrich, Jordi Rodon, Júlia Vergara-Alert, Joaquim Segalés, Victor Guallar, Alfonso Valencia, Nuria Izquierdo-Useros, Roger Paredes, Lourdes Mateu, Anna Chamorro, Marta Massanella, Jorge Carrillo, Bonaventura Clotet, and Julià Blanco**




**Figure S1. Patient and sampling distribution across the follow-up period, related to Figure 1.** Top panels show the time points for sample collection among mild/asymptomatic (a) and hospitalized (b) individuals. Bottom panels show the time points for samples of individuals with a single measurement: c, mild/asymptomatic; d, hospitalized. Time count starts on the day of symptom onset, except for asymptomatic individuals, for whom the serological diagnosis was considered. The areas define the periods considered for the longitudinal analysis: days 0-30 (white), 30-80 (dark grey) and after 80 days (light grey).


a



b



**Figure S2. Longitudinal analysis of neutralizing activity with gender comparison, related to Figure 2.** **a**, Analysis of figure 2a (mild/asymptomatic participants) comparing males (green dots) and females (yellow dots). Linear mixed model is shown for males (black lines) and female (brown line). No effect of gender was detected ( $p=0.75$ , likelihood ratio test). Time points preceding day 30 as well as participants only showing undetectable titers were excluded from the analysis, values are shown but grayed out. **b**, Equivalent reanalysis for figure 2b. Statistical difference between the male and female during the initial slope (day 30-80;  $p=0.014$ , likelihood ratio test initial slope, asterisk) but not the second slope (day >80;  $p=0.16$ , likelihood ratio test).



**Figure S3. Antibody titers at the end of the follow-up period, related to Figure 3.** Antibody titers of the last measure for IgG against the receptor binding domain (RBD) (a), S2 (b), and nucleoprotein (NP) (c) on a subset of individuals with largest follow-up (n=14 for mild/asymptomatic and n=14 for hospitalized). Panel d shows the neutralizing activity of the same subset of individuals at the end of the follow-up period. Boxes show the median and the interquartile range, and bars the 10<sup>th</sup> and 90<sup>th</sup> percentiles. Severity groups (i.e., mild/asymptomatic and hospitalized) were compared using the Mann-Whitney test.